# A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

> **NCT03547115** · PHASE1 · TERMINATED · sponsor: **MEI Pharma, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Small Lymphocytic Lymphoma (SLL)
- Chronic Lymphocytic Leukemia (CLL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** voruciclib monotherapy
- **DRUG:** voruciclib and venetoclax

## Key facts

- **NCT ID:** NCT03547115
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-31
- **Primary completion:** 2024-07-24
- **Final completion:** 2024-07-24
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Business reasons, not related to safety or efficacy results.
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03547115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03547115, "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03547115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*